grant

Cancer Genetics of Long Telomere Syndromes

Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 10 Mar 2025Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY20260-11 years old21+ years oldAML - Acute Myeloid LeukemiaATM Gene MutationATM mutationAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAdultAdult HumanAffectAgeAgingAllelesAllelomorphsAnimal ModelAnimal Models and Related StudiesAntimorphic mutationApoptosisApoptosis PathwayAreaB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBRCA 1/2BRCA 1/2 mutationsBRCA mutantsBRCA mutationsBRCA1/2BRCA1/2 mutationsBRCA1/2mutBRCAmutBindingBlood Precursor CellBody TissuesBreast CancerCancer GenesCancer InductionCancer-Promoting GeneCancersCandidate Disease GeneCandidate GeneCell AgingCell BodyCell SenescenceCell Senescence InductionCellsCellular AgingCellular SenescenceChildChild YouthChildhoodChildhood CancersChildhood NeoplasmChildhood TumorChildren (0-21)ClinicalClinical geneticsClonal expansion of hematopoietic cellsClonal expansion of hematopoietic stem cellsClonal hematopoietic expansionDNA BindingDNA Binding InteractionDNA boundDNA mutationDNA-Binding ProteinsDataData BasesDatabasesDimerizationDiseaseDisorderDominant NegativeDominant-Negative MutantDominant-Negative MutationDonor personDysmyelopoietic SyndromesEC 2.7.7.49Early DiagnosisElongation by TelomeraseEpitheliumEvolutionFailureFamiliar Malignant NeoplasmFamilyGWA studyGWASGenerationsGenesGeneticGenetic ChangeGenetic ModelsGenetic PredispositionGenetic Predisposition to DiseaseGenetic SusceptibilityGenetic defectGenetic mutationGenetic propensityGerm LinesGerm-Line MutationGlial Cell TumorsGlial NeoplasmGlial TumorGliomaGoalsHSC transplantationHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHematopoietic Progenitor CellsHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHematopoietic stem cellsHereditary CancerHereditary Malignant NeoplasmHereditary MutationHeritabilityHeterogeneityHeterozygoteHumanImmuneImmunesImpairmentIn VitroIndividualInherited PredispositionInherited SusceptibilityKnowledgeLengthLifeLinkMalignantMalignant - descriptorMalignant Breast NeoplasmMalignant Childhood NeoplasmMalignant Childhood TumorMalignant Hematologic NeoplasmMalignant MelanomaMalignant NeoplasmsMalignant Pediatric NeoplasmMalignant Pediatric TumorMalignant Soft Tissue NeoplasmMalignant Thyroid Gland NeoplasmMalignant TumorMalignant Tumor of the ThyroidMalignant Tumor of the Thyroid GlandMalignant childhood cancerMalignant neoplasm of thyroidMediatingMedical GeneticsMelanomaMetachronous NeoplasmsMetachronous Second Primary NeoplasmsMiceMice MammalsMissense MutationModelingModern ManMolecular InteractionMurineMusMutant Strains MiceMutationMyelodysplastic DiseaseMyelodysplastic SyndromesNeuroglial NeoplasmNeuroglial TumorOncogenesPIN2Papillary Thyroid CancerPapillary Thyroid Gland CancerPapillary thyroid carcinomaPathogenicityPatient CarePatient Care DeliveryPediatric NeoplasmPediatric TumorPenetrancePhenocopyPhenotypePhylogenetic AnalysisPhylogeneticsPopulationPredisposing FactorPredispositionPredisposition genePrevalencePreventionPrevention ProtocolsProgrammed Cell DeathProtein DimerizationPublishingRNA TranscriptaseRNA-Dependent DNA PolymeraseRNA-Directed DNA PolymeraseRefractory Anemia with an Excess of BlastsRefractory anaemia with excess blastsRegulationReplicative SenescenceReportingResearch ResourcesResourcesReverse TranscriptaseRevertaseRiskRisk FactorsRoleSarcomaScreening for cancerSecond CancerSecond MalignancySecond NeoplasmSecond Primary CancersSecond Primary NeoplasmsSecondary MalignancySecondary Malignant NeoplasmSmoldering LeukemiaSomatic MutationSurvivorsSusceptibilitySusceptibility GeneSyndromeT-CellsT-LymphocyteTCGATEBPTERF1TERF1 geneTIN2TINF2TINF2 geneTRF GeneTRF ProteinTRF1TRF1-Interacting Nuclear Factor 2TelomeraseTelomere End-Binding ProteinTelomere Length MaintenanceTelomere MaintenanceTelomere-Binding ProteinsTelomeric Repeat Binding Factor 1TestingThe Cancer Genome AtlasThyroid CancerThyroid Gland Papillary CarcinomaTissuesTransforming GenesTumor Suppressor ProteinsUpregulationVariantVariationWorkacute granulocytic leukemiaacute myeloid leukemiaadulthoodage associatedage correlatedage dependentage linkedage relatedage specificagesataxia telangiectasia mutated gene mutationataxia telangiectasia mutated mutationautosomebiomarker identificationblood cell progenitorblood progenitorblood stem cellblood stem cell transplantationblood-forming stem cellbrca genecancer geneticscancer in a childcancer in childrencancer predispositioncancer riskcancer typecarcinogenesiscare for patientscare of patientscaring for patientscell free DNAcell free circulating DNAcellular aging inductioncellular longevitycellular senescence inductioncheck point blockadecheckpoint blockadechild with cancerchildhood malignancyclonal expansions in the bloodclonal hematopoiesisclones in hematopoietic cellscustomized therapycustomized treatmentdata basedefined contributiondimerdisease durationdisease lengthearly cancer detectionearly detectionearly onsetexhaustionexperimentexperimental researchexperimental studyexperimentsfamilial cancergene testinggene-based testinggenetic testinggenetic vulnerabilitygenetically engineered cellsgenetically modified cellsgenetically predisposedgenome mutationgenome wide associationgenome wide association scangenome wide association studygenomewide association scangenomewide association studygerm-line defectgermline variantglial-derived tumorhematopoietic cell cloneshematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitorhematopoietic progenitor cell transplantationhematopoietic stem cell clonalityhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellheterozygosityhigh risk grouphigh risk individualhigh risk peoplehigh risk populationidentification of biomarkersidentification of new biomarkersillness lengthimmune check point blockadeimmune checkpoint blockadein vivoin vivo Modelindividualized medicineindividualized patient treatmentindividualized therapeutic strategyindividualized therapyindividualized treatmentkidsknock-downknockdownleukemialife spanlifespanmalignancymalignant breast tumormalignant soft tissue tumormarker identificationmissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmodel of animalmouse mutantmutantmutation carriermutations in BRCAmyelodysplasianeoplasm/cancerneuroglia neoplasmneuroglia tumornovelpatient specific therapiespatient specific treatmentpediatricpediatric cancerpediatric malignancypredisposing genepublic data basepublic databasepublicly accessible data basepublicly accessible databasepublicly available data basepublicly available databasereplicative agingscreeningscreening cancer patientsscreeningssecondary cancersenescence inductionsequencing platformsocial rolesomatic variantsusceptibility allelesusceptibility locussusceptibility varianttailored medical treatmenttailored therapytailored treatmenttelomerethymus derived lymphocytetransplant donortumortumor suppressortumors in childrenunique treatmentwhole genome association analysiswhole genome association studyyoungster
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Abstract
This application focuses on understanding the genetic basis of a recently recognized cancer-prone syndrome

caused by long telomere length. It is driven by extended cellular longevity, a mechanism that is distinct from

tumor suppressor- and oncogene-mediated familial cancer syndromes. Telomere length is constrained in the

human population…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →